

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021205 001	ABACAVIR SULFATE;TRIZIVIR	5034394	JUN 26, 2009		NCE	NOV 17, 2000
		5089500	JUN 26, 2009	U-248	NCE	DEC 17, 2003
		5047407	NOV 17, 2009			
		5905082	MAY 18, 2016			
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4833130	SEP 17, 2005			
		4837208	SEP 17, 2005			
		4828838	SEP 17, 2005			
075077 001	ACETAMINOPHEN;ACETAMINOPHEN				PC	NOV 12, 2000
020338 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010			
020380 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010			
020748 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010		NCE	MAY 31, 2001
		RE34440	MAY 31, 2010	U-275	NDF	MAY 26, 2003
020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6080756	JUL 05, 2016			
020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6080756	JUL 05, 2016			
020560 001	ALENDRONATE SODIUM;FOSAMAX	6008207	JUN 06, 2015	U-303	M-3	NOV 24, 2002
		6090410	DEC 02, 2012		I-309	SEP 29, 2003
020560 002	ALENDRONATE SODIUM;FOSAMAX	6008207	JUN 06, 2015	U-303	M-3	NOV 24, 2002
		6090410	DEC 02, 2012			
020560 003	ALENDRONATE SODIUM;FOSAMAX	6008207	JUN 06, 2015	U-303	M-3	NOV 24, 2002
		6090410	DEC 02, 2012			
>ADD> >ADD>	020560 004	ALENDRONATE SODIUM;FOSAMAX	6090410	DEC 02, 2012	NS	OCT 20, 2003
		5994329	JUL 17, 2018		D-61	OCT 20, 2003
		6015801	JUL 17, 2018	U-353	D-62	OCT 20, 2003
		4621077	AUG 06, 2007	U-114		
		5358941	DEC 02, 2012			
		5681590	DEC 02, 2012			
		5804570	FEB 17, 2015			
		5849726	JUN 06, 2015			
		6008207	JUN 06, 2015			
>ADD>	020560 005	ALENDRONATE SODIUM;FOSAMAX	6090410	DEC 02, 2012	NS	OCT 20, 2003
		6015801	JUL 17, 2018	U-353	D-61	OCT 20, 2003
		4621077	AUG 06, 2007	U-114	D-62	OCT 20, 2003
		5358941	DEC 02, 2012			
		5681590	DEC 02, 2012			
		5804570	FEB 17, 2015			
		5849726	JUN 06, 2015			
		5994329	JUL 17, 2018			
		6008207	JUN 06, 2015			
021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX				NCE	FEB 09, 2005
018276 001	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
018276 002	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		
018276 003	ALPRAZOLAM;XANAX	4508726	SEP 16, 2002	U-46		

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018276 004	ALPRAZOLAM; XANAX	4508726	SEP 16, 2002	U-46		
020221 001	AMIFOSTINE; ETHYOL				I-283	JUN 24, 2002
020221 002	AMIFOSTINE; ETHYOL				I-283	JUN 24, 2002
>ADD>	020364 002	AMLODIPINE BESYLATE; LOTREL	6162802	DEC 19, 2017	U-367	
>ADD>	020364 003	AMLODIPINE BESYLATE; LOTREL	6162802	DEC 19, 2017	U-367	
>ADD>	020364 004	AMLODIPINE BESYLATE; LOTREL	6162802	DEC 19, 2017	U-367	
020508 001	AMMONIUM LACTATE; LAC-HYDRIN				M-4	AUG 25, 2003
021007 001	AMPRENAVIR; AGENERASE	5723490	MAR 03, 2013	U-257		
		5646180	JUL 08, 2014	U-257		
		5585397	DEC 17, 2013			
021007 002	AMPRENAVIR; AGENERASE	5723490	MAR 03, 2015	U-257		
		5646180	JUL 08, 2014	U-257		
		5585397	DEC 17, 2013			
021039 001	AMPRENAVIR; AGENERASE	5723490	MAR 03, 2015	U-257		
		5646180	JUL 08, 2014	U-257		
020541 001	ANASTROZOLE; ARIMIDEX	RE36617	DEC 27, 2009		I-312	SEP 01, 2003
020883 001	ARGATROBAN; ACOVA				NCE	JUN 30, 2005
021248 001	ARSENIC TRIOXIDE; TRISENOX				ODE	SEP 25, 2007
					NCE	SEP 25, 2005
					NC	APR 03, 2003
020971 001	ARTICAINE HYDROCHLORIDE; SEPTOCAINE					
>ADD>	020702 001	ATORVASTATIN CALCIUM; LIPITOR	6126971	JAN 19, 2013		
>ADD>	020702 002	ATORVASTATIN CALCIUM; LIPITOR	6126971	JAN 19, 2013		
>ADD>	020702 003	ATORVASTATIN CALCIUM; LIPITOR	6126971	JAN 19, 2013		
>ADD>	020702 004	ATORVASTATIN CALCIUM; LIPITOR	6126971	JAN 19, 2013		
		4681893	SEP 24, 2009	U-161	I-281	DEC 02, 2002
		5273995	DEC 28, 2010	U-162	I-218	JUL 10, 2001
		5686104	NOV 11, 2014	U-213	I-219	JUL 10, 2001
		5969166	JUL 08, 2016			
021127 001	AZELASTINE HYDROCHLORIDE; OPTIVAR	5164194	NOV 01, 2010		NCE	NOV 01, 2001
		5164194*	MAY 01, 2011		NDF	MAY 22, 2003
					PED	MAY 01, 2002
					PED	NOV 22, 2003
020610 001	BALSALAZIDE DISODIUM; COLAZAL	4412992	JUL 08, 2001		NCE	JUL 18, 2005
020911 002	BECLOMETHASONE DIPROPIONATE; QVAR 40	5776432	JUL 07, 2015			
		5605674	FEB 25, 2014			
		5695743	JUL 06, 2010			
		5683677	NOV 04, 2014			
		5766573	NOV 28, 2009	U-356		
020911 001	BECLOMETHASONE DIPROPIONATE; QVAR 80	5776432	JUL 07, 2015			
		5605674	FEB 25, 2014			
		5695743	JUL 06, 2010			
		5683677	NOV 04, 2014			
		5766573	NOV 28, 2009	U-356		
020010 001	BETAMETHASONE DIPROPIONATE; LOTRISONE				NP	DEC 08, 2003

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021055 001	BEXAROTENE; TARGRETIN				ODE	DEC 29, 2006
021056 001	BEXAROTENE; TARGRETIN				NCE	DEC 29, 2004
					NDF	JUN 28, 2003
019982 001	BISOPROLOL FUMARATE; ZEBETA	4258062	MAR 24, 2000	U-63		
		4258062*PED	SEP 24, 2000	U-63		
019982 002	BISOPROLOL FUMARATE; ZEBETA	4258062	MAR 24, 2000	U-63		
		4258062*PED	SEP 24, 2000	U-63		
020186 001	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 2000	U-63		
		4258062*PED	SEP 24, 2000	U-63		
020186 002	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 2000	U-63		
		4258062*PED	SEP 24, 2000	U-63		
020186 003	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 2000	U-63		
		4358062*PED	SEP 24, 2000	U-63		
>ADD> 020873 001	BIVALIRUDIN; ANGIOMAX				NCE	DEC 15, 2005
050443 002	BLEOMYCIN SULFATE; BLENOXANE				ODE	FEB 20, 2003
020929 001	BUDESONIDE; PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
020929 002	BUDESONIDE; PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
020711 002	BUPROPION HYDROCHLORIDE; ZYBAN				D-54	SEP 10, 2002
020711 003	BUPROPION HYDROCHLORIDE; ZYBAN				D-54	SEP 10, 2002
018731 001	BUSPIRONE HYDROCHLORIDE; BUSPAR	4182763	MAY 22, 2000	U-13		
		5015646	MAY 14, 2008			
		4182763*PED	NOV 22, 2000	U-13		
		5015646*PED	NOV 14, 2008			
		6150365	AUG 05, 2019	U-361		
018731 002	BUSPIRONE HYDROCHLORIDE; BUSPAR	4182763	MAY 22, 2000	U-13		
		5015646	MAY 14, 2008			
		4182763*PED	NOV 22, 2000	U-13		
		5015646*PED	NOV 14, 2008			
		6150365	AUG 05, 2019	U-361		
018731 003	BUSPIRONE HYDROCHLORIDE; BUSPAR	5015646	MAY 14, 2008			
		4182763	MAY 22, 2000	U-13		
		4182763*PED	NOV 22, 2000	U-13		
		5015646*PED	NOV 14, 2008			
		6150365	AUG 05, 2019	U-361		
018731 004	BUSPIRONE HYDROCHLORIDE; BUSPAR	4182763	MAY 22, 2000	U-13		
		5015646	MAY 14, 2008			
		4182763*PED	NOV 22, 2000			
		5015646*PED	NOV 14, 2008	U-13		
		6150365	AUG 05, 2019	U-361		
020793 001	CAFFEINE CITRATE; CAFKIT				ODE	SEP 21, 2006
020313 002	CALCITONIN, SALMON; MIACALCIN	5759565	MAR 31, 2015			
018874 001	CALCITRIOL; CALCIJEX	6051567	AUG 02, 2019			
018874 002	CALCITRIOL; CALCIJEX	6051567	AUG 02, 2019			

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020958 001	CALCIUM CARBONATE, PRECIPITATED;PEPCID COMPLETE	5229137	MAY 16, 2012	U-349	NC	OCT 15, 2003
		4283408	OCT 15, 2000		PED	APR 15, 2004
		5817340	DEC 01, 2012			
		5989588	SEP 30, 2015	U-349		
		5989588*PED	MAR 30, 2018	U-349		
		4283408*PED	APR 15, 2001			
		5229137*PED	NOV 16, 2012			
021093 001	CANDESARTAN CILEXETIL;ATACAND HCT	5817340*PED	JUN 01, 2013			
		5705517	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5721263	FEB 24, 2015	U-3	NC	SEP 05, 2003
		5958961	JUN 06, 2014	U-3		
		5196444	APR 18, 2011	U-3		
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011	U-3		
021093 002	CANDESARTAN CILEXETIL;ATACAND HCT	5705517	APR 18, 2011	U-3	NCE	JUN 04, 2003
		5721263	FEB 24, 2015	U-3	NC	SEP 05, 2003
		5958961	JUN 06, 2014	U-3		
		5196444	APR 18, 2011	U-3		
		5534534	JUL 09, 2013			
		5703110	APR 18, 2011	U-3		
		4966891	JAN 13, 2011	U-272		
020896 001	CAPECITABINE;XELODA	4966891	JAN 13, 2011	U-272		
020896 002	CAPECITABINE;XELODA	4966891	JAN 13, 2011	U-272		
020297 001	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
020297 002	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
020297 003	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
020297 004	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
020740 001	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
					I-303	JUL 21, 2003
020740 002	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
					I-303	JUL 21, 2003
020740 003	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
					I-303	JUL 21, 2003
020740 004	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
					I-303	JUL 21, 2003
020740 005	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
					I-303	JUL 21, 2003
020740 006	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		D-59	JUL 21, 2003
		5177080	JAN 26, 2011		I-303	JUL 21, 2003
					NS	JUL 21, 2003
021197 001	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
		5198533	JUL 17, 2007			
021197 002	CETRORELIX;CETROTIDE	4800191	JUL 17, 2007		NCE	AUG 11, 2005
		5198533	JUL 17, 2007			
020989 002	CEVIMELINE HYDROCHLORIDE;EVOXAC	4855290	AUG 08, 2006		NCE	JAN 11, 2005
		5340821	AUG 23, 2011	U-309		
		5580880	JUN 06, 2015	U-310		

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020832 001	CHLORHEXIDINE GLUCONATE;CHLORAPREP				NC	JUL 14, 2003
021149 002	CHORIOGONADOTROPIN ALFA;OVIDREL	5767251	JUN 16, 2015		NP	SEP 20, 2003
020780 001	CIPROFLOXACIN;CIPRO	6136347	JAN 06, 2013	U-362		
020780 002	CIPROFLOXACIN;CIPRO	6136347	JAN 06, 2013	U-362		
020822 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
021046 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
021142 001	CLOBETASOL PROPIONATE;OLUX FOAM				NDF	MAY 26, 2003
021143 001	CLOTTRIMAZOLE;TRIVAGIZOLE 3				NP	NOV 24, 2001
021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5624963	APR 29, 2014	U-323	NCE	MAY 26, 2005
		5679717	APR 29, 2014	U-323		
		5693675	DEC 02, 2014			
		5607669	JUN 10, 2014	U-323		
		5917007	APR 29, 2014	U-323		
		5919832	JUN 10, 2014			
021176 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5919832	JUN 10, 2014		NCE	MAY 26, 2005
		5917007	APR 29, 2014	U-323		
		5607669	JUN 10, 2014	U-323		
		5693675	DEC 02, 2014			
		5679717	APR 29, 2014	U-323		
		5624963	APR 29, 2014	U-323		
020287 001	DALTEPARIN SODIUM;FRAGMIN				D-60	AUG 03, 2003
020287 003	DALTEPARIN SODIUM;FRAGMIN				D-60	AUG 03, 2003
020287 004	DALTEPARIN SODIUM;FRAGMIN				D-60	AUG 03, 2003
020713 001	DESOGESTREL;MIRCETTE	RE35724	OCT 20, 2008			
020212 001	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U-339		
		4963551	DEC 21, 2007			
		4275063	JUN 23, 2003			
020212 002	DEXRAZOXANE HYDROCHLORIDE;ZINECARD	5242901	SEP 07, 2010	U-339		
		4963551	DEC 21, 2007			
		4275063	JUN 23, 2003			
020154 002	DIDANOSINE;VIDEX				D-58	OCT 28, 2002
020154 003	DIDANOSINE;VIDEX				D-58	OCT 28, 2002
020154 004	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180	D-58	OCT 28, 2002
020154 005	DIDANOSINE;VIDEX				D-58	OCT 28, 2002
020154 006	DIDANOSINE;VIDEX				NS	OCT 28, 2002
					D-58	OCT 28, 2002
021183 001	DIDANOSINE;VIDEX EC				NDF	OCT 31, 2003
021183 002	DIDANOSINE;VIDEX EC				NDF	OCT 31, 2003
021183 003	DIDANOSINE;VIDEX EC				NDF	OCT 31, 2003
021183 004	DIDANOSINE;VIDEX EC				NDF	OCT 31, 2003
020939 001	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			
020939 002	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
		5529791	JUN 25, 2013			

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES	EXCLUS CODE	EXCLUS EXPIRES
020939 003	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011		
		5529791	JUN 25, 2013		
020939 004	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011		
		5529791	JUN 25, 2013		
021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	4988731	JAN 29, 2008	NP	AUG 04, 2003
		4913906	APR 03, 2007		
020941 001	DOCOSANOL;ABREVA			NCE	JUL 25, 2005
020931 001	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		
020931 002	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		
020931 003	DOFETILIDE;TIKOSYN	6124363	OCT 09, 2018		
>ADD>	020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	JUL 02, 2011	
			4906775	JUL 02, 2011	
>ADD>	020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	JUL 02, 2011	
			4906775	JUL 02, 2011	
>ADD>	020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	JUL 02, 2011	
	020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	6140321	JUN 07, 2014	
	020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	6140321	JUN 07, 2014	
	020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	4797413	APR 28, 2008	
			4619939	OCT 28, 2003	
	021027 001	DOXERCALCIFEROL;HECTOROL	5602116	APR 03, 2115	U-103
			5707980	FEB 11, 2117	U-104
	021145 001	EFLORNITHINE HYDROCHLORIDE;VANIQA	4413141	NOV 01, 2000	U-321 NDF
			4720489	JAN 19, 2005	U-321 NCE
			5648394	JUL 15, 2014	NP
			4472380	SEP 18, 2001	JUN 09, 2004
			4374829	FEB 22, 2000	JUL 27, 2003
	019221 001	ENALAPRIL MALEATE;VASERETIC	4374829*PED	AUG 22, 2000	
			4472380*PED	MAR 18, 2002	
	019221 003	ENALAPRIL MALEATE;VASERETIC	4472380	SEP 18, 2001	
			4374829	FEB 22, 2000	
			4374829*PED	AUG 22, 2000	
			4472380*PED	MAR 18, 2002	
	018998 001	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000	
			4374829*PED	AUG 22, 2000	
	018998 002	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000	
			4374829*PED	AUG 22, 2000	
	018998 003	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000	
			4374829*PED	AUG 22, 2000	
	018998 005	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000	
			4374829*PED	AUG 22, 2000	
	019309 001	ENALAPRILAT;VASOTEC	4374829	FEB 22, 2000	
			4374829*PED	AUG 22, 2000	
	020164 001	ENOXAPARIN SODIUM;LOVENOX			I-315
	020164 002	ENOXAPARIN SODIUM;LOVENOX			I-315

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES	EXCLUS CODE	EXCLUS EXPIRES
020164 003	ENOXAPARIN SODIUM;LOVENOX			I-315	NOV 17, 2003
020164 004	ENOXAPARIN SODIUM;LOVENOX			I-315	NOV 17, 2003
020164 005	ENOXAPARIN SODIUM;LOVENOX			I-315	NOV 17, 2003
020444 001	EPOPROSTENOL SODIUM;FLOLAN			ODE	APR 14, 2007
020444 002	EPOPROSTENOL SODIUM;FLOLAN			I-296	APR 14, 2003
				ODE	APR 14, 2007
				I-296	APR 14, 2003
020874 001	ESTRADIOL CYPIONATE;LUNELLE			NP	OCT 05, 2003
020907 001	ESTRADIOL;ACTIVELLE	RE36247	MAY 02, 2006	I-295	APR 11, 2003
020655 001	ESTRADIOL;ALORA	5122383	MAY 17, 2011		
		5227169	MAY 17, 2011		
		5212199	MAY 17, 2011		
		5164190	DEC 11, 2010		
020655 002	ESTRADIOL;ALORA	5122383	MAY 17, 2011		
		5227169	MAY 17, 2011		
		5212199	MAY 17, 2011		
		5164190	DEC 11, 2010		
020655 003	ESTRADIOL;ALORA	5122383	MAY 17, 2011		
		5227169	MAY 17, 2011		
		5212199	MAY 17, 2011		
		5164190	DEC 11, 2010		
021040 001	ESTRADIOL;ORTHO-PREFEST	5108995	APR 28, 2009	U-311	
		5382573	JAN 17, 2012		
020323 001	ESTRADIOL;VIVELLE			I-254	AUG 16, 2003
020323 002	ESTRADIOL;VIVELLE			I-254	AUG 16, 2003
020323 003	ESTRADIOL;VIVELLE			I-254	AUG 16, 2003
020323 004	ESTRADIOL;VIVELLE			I-254	AUG 16, 2003
020323 005	ESTRADIOL;VIVELLE	4994278	MAR 04, 2008	NS	AUG 16, 2003
		5300291	APR 05, 2011	I-254	AUG 16, 2003
		4814168	MAR 04, 2008		
		4994267	MAR 04, 2008		
		5908638	JUL 26, 2015		
020992 002	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015		
020992 003	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015		
020992 004	ESTROGENS, CONJUGATED SYNTHETIC A;CENESTIN	5908638	JUL 26, 2015		
075696 001	ETODOLAC;ETODOLAC			PC	FEB 04, 2001
020584 001	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008		
		4966768	OCT 30, 2007		
020584 002	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008		
		4966768	OCT 30, 2007		
020584 003	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008		
		4966768	OCT 30, 2007		
019462 001	FAMOTIDINE;PEPCID	4283408	OCT 15, 2000		
		4283408*PED	APR 15, 2001		
019462 002	FAMOTIDINE;PEPCID	4283408	OCT 15, 2000		
		4283408*PED	APR 15, 2001		

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019510 001	FAMOTIDINE;PEPCID	4283408	OCT 15, 2000			
		4283408*PED	APR 15, 2001			
019527 001	FAMOTIDINE;PEPCID	4283408	OCT 15, 2000			
		4283408*PED	APR 15, 2001			
020325 001	FAMOTIDINE;PEPCID AC	4283408	OCT 15, 2000		D-47	NOV 09, 2001
		5667794	MAY 02, 2015	U-205	PED	MAY 09, 2002
		5854267	DEC 29, 2015	U-267		
		4283408*PED	APR 15, 2001			
		5667794*PED	NOV 02, 2015	U-205		
		5854267*PED	JUN 29, 2016	U-267		
020801 001	FAMOTIDINE;PEPCID AC	5667794	MAY 02, 2015			
		4283408	OCT 15, 2000			
		5854267	DEC 29, 2015	U-267		
		5075114	DEC 24, 2008			
		4283408*PED	APR 15, 2001			
		5075114*PED	JUN 24, 2009			
		5667794*PED	NOV 02, 2015			
		5854267*PED	JUN 29, 2016			
>ADD>	020902 001	FAMOTIDINE;PEPCID AC	5854267	DEC 29, 2015	U-368	
>ADD>			5854267*PED	JUN 29, 2016	U-368	
>ADD>			5667794	MAY 02, 2015	U-368	
>ADD>			5667794*PED	NOV 02, 2015	U-368	
>ADD>			4820524*PED	AUG 20, 2007		
>ADD>			4820524	FEB 20, 2007		
		4283408	OCT 15, 2000			
		4283408*PED	APR 15, 2001			
019510 004	FAMOTIDINE;PEPCID PRESERVATIVE	4283408	OCT 15, 2000			
		4283408*PED	APR 15, 2001			
020249 001	FAMOTIDINE;PEPCID PRESERVATIVE	4283408	OCT 15, 2000			
		4238408*PED	APR 15, 2001			
020752 001	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000			
		4283408*PED	APR 15, 2001			
020752 002	FAMOTIDINE;PEPCID RPD	4283408	OCT 15, 2000			
		4283408*PED	APR 15, 2001			
019304 002	FENOFIBRATE;TRICOR (MICRONIZED)				I-298	APR 24, 2003
019304 003	FENOFIBRATE;TRICOR (MICRONIZED)				I-298	APR 24, 2003
019304 004	FENOFIBRATE;TRICOR (MICRONIZED)				I-298	APR 24, 2003
020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			
020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015		NCE	JUL 25, 2001
		5855912	FEB 28, 2015			
		4254129	FEB 17, 2001	U-139		
		6037353	MAR 14, 2017	U-138		
		6113942	FEB 28, 2015			



PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020872 002	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015		NCE	JUL 25, 2001
		5855912	FEB 28, 2015	U-139		
		4254129	FEB 17, 2001			
		6037353	MAR 14, 2017			
		6113942	FEB 28, 2015			
020872 004	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
		5932247	FEB 28, 2015		NCE	JUL 25, 2001
		5855912	FEB 28, 2015	U-139		
		4254129	FEB 17, 2001			
		6037353	MAR 14, 2017			
		6113942	FEB 28, 2015			
020786 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA-D	6037353	MAR 14, 2017	U-138		
		6039974	JUL 31, 2018			
		6113942	FEB 28, 2015			
019949 004	FLUCONAZOLE; DIFLUCAN	4416682	JUN 02, 2001			
		4404216	JAN 29, 2004			
020985 001	FLUOROURACIL; FLUOROURACIL				NP	OCT 27, 2003
018936 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4626549	DEC 02, 2003	U-154		
		4314081	FEB 02, 2001			
		4626549	DEC 02, 2003	U-84		
		4314081*PED	AUG 02, 2001			
		4626549*PED	JUN 02, 2004			
		4626549*PED	JUN 02, 2004			
018936 003	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001	U-154		
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003	U-84		
		4314081*PED	AUG 02, 2001			
		4626549*PED	JUN 02, 2004			
		4626549*PED	JUN 02, 2004			
018936 004	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001	U-154		
		4314081*PED	AUG 02, 2001			
		4626549	DEC 02, 2003	U-84		
		4626549	DEC 02, 2003			
		4626549*PED	JUN 02, 2004			
		4626549*PED	JUN 02, 2004			
018936 006	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001	U-154		
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003	U-84		
		4314081*PED	AUG 02, 2001			
		4626549*PED	JUN 02, 2004			
		4626549*PED	JUN 02, 2004			
020101 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4314081	FEB 02, 2001	U-84		
		4626549	DEC 02, 2003			
		4626549	DEC 02, 2003	U-154		
		4314081*PED	AUG 02, 2001			
		4626549*PED	JUN 02, 2004			
		4626549*PED	JUN 02, 2004			

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020974 001	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549	DEC 02, 2003	U-84		
		4626549	DEC 02, 2003	U-154		
		4314081	FEB 02, 2001			
		4314081*PED	AUG 02, 2001			
		4626549*PED	JUN 02, 2004	U-84		
020974 002	FLUOXETINE HYDROCHLORIDE;PROZAC	4626549*PED	JUN 02, 2004	U-154		
		4626549	DEC 02, 2003	U-84		
		4626549	DEC 02, 2003	U-154		
		4314081	FEB 02, 2001			
		4314081*PED	AUG 02, 2001			
018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM	4626549*PED	JUN 02, 2004	U-84		
		4626549*PED	JUN 02, 2004	U-154		
		4971998	NOV 20, 2007	U-338	NP	JUL 06, 2003
		5114976	MAY 19, 2009	U-341	PED	JUN 06, 2004
		5744501	MAY 19, 2009	U-342		
018936 008	FLUOXETINE HYDROCHLORIDE;SARAFEM	4971998*PED	MAY 20, 2008	U-338		
		5114976*PED	NOV 19, 2009	U-341		
		5744501*PED	NOV 19, 2009	U-342		
		4971998	NOV 20, 2007	U-338	NP	JUL 06, 2003
		5114976	MAY 19, 2009	U-341	PED	JAN 06, 2004
021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	5744501	MAY 19, 2009	U-342		
		4971998*PED	MAY 20, 2008	U-338		
		5114976*PED	NOV 19, 2009	U-341		
		5744501*PED	NOV 19, 2009	U-342		
		4335121	NOV 14, 2003		NC	AUG 24, 2003
021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	5270305	SEP 07, 2010			
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
		4335121	NOV 14, 2003		NC	AUG 24, 2003
021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	5270305	SEP 07, 2010			
		4992474	FEB 12, 2008	U-211		
		5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
		4335121	NOV 14, 2003		NC	AUG 24, 2003
021192 001	FLUVASTATIN SODIUM;LESCOL XL	5270305	SEP 07, 2010		NDF	OCT 06, 2003
		4992474	FEB 12, 2008	U-211		
020378 001	FOLLITROPIN ALFA/BETA;GONAL-F	5225445	FEB 12, 2008	U-211		
		5126375	FEB 12, 2008			
020378 002	FOLLITROPIN ALFA/BETA;GONAL-F					

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020378 003	FOLLITROPIN ALFA/BETA;GONAL-F	4589402	JUL 26, 2004	U-242	I-306	MAY 24, 2003
>ADD> 020696 001	FOMEPIZOLE;ANTIZOL	5767251	JUN 16, 2015		ODE	MAY 24, 2007
020235 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86	PED	MAR 29, 2002
		5084479	JAN 02, 2010	U-125	D-43	SEP 29, 2001
		4894476*PED	NOV 02, 2008		I-311	OCT 12, 2003
		4087544*PED	JUL 16, 2000	U-86		
		5084479*PED	JUL 02, 2010	U-125		
		4894476	MAY 02, 2008			
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			
020235 002	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		PED	MAR 29, 2002
		5084479	JAN 02, 2010	U-125	D-43	SEP 29, 2001
		4087544	JAN 16, 2000	U-86	I-311	OCT 12, 2003
		5084479*PED	JUL 02, 2010	U-125		
		4894476*PED	NOV 02, 2008			
		4087544*PED	JUL 16, 2000	U-86		
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			
020235 003	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86	PED	MAR 29, 2002
		5084479	JAN 02, 2010	U-125	D-43	SEP 29, 2001
		4894476	MAY 02, 2008		I-311	OCT 12, 2003
		4087544*PED	JUL 16, 2000	U-86		
		5084479*PED	JUL 02, 2010			
		4894476*PED	NOV 02, 2008			
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			
020882 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106	I-311	OCT 12, 2003
		4894476	MAY 02, 2008			
		5084479	JAN 02, 2010	U-258		
		5084479*PED	JUL 02, 2010	U-258		
		4087544*PED	JUL 16, 2000	U-106		
		4894476*PED	NOV 02, 2008			
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			
020882 002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106	I-311	OCT 12, 2003
		4894476	MAY 02, 2008			
		5084479	JAN 02, 2010	U-258		
		4087544*PED	JUL 16, 2000	U-106		
		4894476*PED	NOV 02, 2008			
		5084479*PED	JUL 02, 2010	U-258		
		6054482	APR 25, 2017			
		6054482*PED	OCT 25, 2017			
021129 001	GABAPENTIN;NEURONTIN				I-311	OCT 12, 2003

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021037 001	GADOPENTETATE DIMEGlumINE; MAGNEVIST	5362475	NOV 08, 2011			
		5560903	OCT 01, 2013			
		4647447	MAR 03, 2004			
		4957939	MAR 03, 2004			
		4963344	MAR 03, 2004			
020460 002	GANCICLOVIR; CYTOVENE	4507305	MAY 21, 2001	U-64		
		4423050	MAY 21, 2001	U-64		
		4355032	JUN 23, 2003	U-64		
		4642346	JUN 24, 2005			
021174 001	GEMTUZUMAB OZOGAMICIN; MYLOTARG	5606040	FEB 25, 2014		ODE	MAY 17, 2007
		5693762	DEC 02, 2014		NCE	MAY 17, 2005
		5739116	APR 14, 2015			
		5767285	JUN 16, 2015			
		5773001	JUN 30, 2015	U-320		
		4970198	NOV 30, 2007			
		5079233	JAN 07, 2009			
		5585089	DEC 17, 2013			
020622 001	GLATIRAMER ACETATE; COPAXONE	5981589	MAY 24, 2014			
		6054430	MAY 24, 2014			
021178 001	GLYBURIDE; GLUCOVANCE				NC	JUL 31, 2003
021178 002	GLYBURIDE; GLUCOVANCE				NC	JUL 31, 2003
021178 003	GLYBURIDE; GLUCOVANCE				NC	JUL 31, 2003
020125 001	HYDROCHLOROTHIAZIDE; ACCURETIC				NC	DEC 28, 2002
020125 002	HYDROCHLOROTHIAZIDE; ACCURETIC				NC	DEC 28, 2002
020125 003	HYDROCHLOROTHIAZIDE; ACCURETIC				NC	DEC 28, 2002
020387 002	HYDROCHLOROTHIAZIDE; HYZAAR	5138069	AUG 11, 2009			
		5153197	OCT 06, 2009	U-3		
021162 001	HYDROCHLOROTHIAZIDE; MICARDIS HCT	5591762	JAN 07, 2014	U-3	NC	NOV 17, 2003
021162 002	HYDROCHLOROTHIAZIDE; MICARDIS HCT	5591762	JAN 07, 2014	U-3	NC	NOV 17, 2003
019778 001	HYDROCHLOROTHIAZIDE; PRINZIDE	4374829	DEC 29, 2001			
019778 002	HYDROCHLOROTHIAZIDE; PRINZIDE	4374829	DEC 29, 2001			
019778 003	HYDROCHLOROTHIAZIDE; PRINZIDE	4374829	DEC 29, 2001	U-3		
>ADD>	019888 001	HYDROCHLOROTHIAZIDE; ZESTORETIC	4374829	DEC 29, 2001	U-3	
>ADD>	019888 002	HYDROCHLOROTHIAZIDE; ZESTORETIC	4374829	DEC 29, 2001	U-3	
>ADD>	019888 003	HYDROCHLOROTHIAZIDE; ZESTORETIC	4374829	DEC 29, 2001	U-3	
	019771 001	IBUPROFEN; ADVIL COLD AND SINUS	4552899	APR 09, 2004		
		4552899*PED	OCT 09, 2004			
021128 001	IBUPROFEN; CHILDREN'S MOTRIN CO				NP	AUG 01, 2003
019763 003	IFOSFAMIDE; IFEX/MESNEX KIT	4220660	MAR 06, 2001	U-21		
		5696172	OCT 06, 2013			
019763 004	IFOSFAMIDE; IFEX/MESNEX KIT	4220660	MAR 06, 2001	U-21		
		5696172	OCT 06, 2013			
020986 001	INSULIN ASPART RECOMBINANT; NOVOLOG				NCE	JUN 07, 2005
021081 001	INSULIN GLARGINE; LANTUS				PED	OCT 20, 2005
					NCE	APR 20, 2005

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020563 001	INSULIN LISPRO;HUMALOG				D-56	APR 04, 2003
021018 001	INSULIN LISPRO;HUMALOG MIX 50/50				NC	DEC 22, 2002
021017 001	INSULIN LISPRO;HUMALOG MIX 75/25	5474978	JUN 16, 2014			
		5747642	JUN 16, 2014			
		5461031	JUN 16, 2014			
		5514646	MAY 07, 2013			
020563 002	INSULIN LISPRO;HUMALOG PEN	5474978	JUN 16, 2014		D-56	APR 04, 2003
		5514646	MAY 07, 2013	U-111	NCE	JUN 14, 2001
020571 001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR				I-299	APR 20, 2003
021135 001	IRON SUCROSE;VENOFER				NP	NOV 07, 2003
020966 001	ITRACONAZOLE;SPORANOX	4727064	FEB 23, 2005			
019084 001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			
020811 001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE	4454151	MAR 22, 2002			
020857 001	LAMIVUDINE;COMBIVIR	4828838*	PED MAR 17, 2006		NCE	NOV 17, 2000
		4833130*	PED MAR 17, 2006		PED	MAY 17, 2001
		4837208	SEP 17, 2005			
		5047407*	PED AUG 08, 2009			
		4724232*	PED MAR 17, 2006			
		4818538*	PED MAR 17, 2006			
		5859021*	PED NOV 15, 2012	U-248		
		5905082*	PED NOV 18, 2016	U-248		
		6113920	OCT 23, 2017	U-257		
		6113920*	PED APR 23, 2018	U-257		
		4724232	SEP 17, 2005			
		4818538	SEP 17, 2005			
		4828838	SEP 17, 2005			
		4833130	SEP 17, 2005			
		5047407	FEB 08, 2009			
		5859021	MAY 15, 2012	U-248		
		5905082	MAY 18, 2016	U-248		
		4837208*	PED MAR 17, 2006			
020564 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		NCE	NOV 17, 2000
		5905082	MAY 18, 2016		PED	MAY 17, 2001
		5905082*	PED NOV 18, 2016			
		5047407*	PED MAY 17, 2010			
020596 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009		NCE	NOV 17, 2000
		6004968	MAR 20, 2018		PED	MAY 17, 2001
		6004968*	PED SEP 20, 2018			
		5047407*	PED MAY 17, 2010			
021003 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		I-257	DEC 08, 2001
		5532246	JUL 02, 2013	U-250	PED	JUN 08, 2002
		5905082	MAY 18, 2016			
		5047407*	PED AUG 08, 2009			
		5532246*	PED JAN 02, 2014	U-250		
		5905082*	PED NOV 18, 2016			

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021004 001	LAMIVUDINE;EPIVIR-HBV	5047407	FEB 08, 2009		NCE	NOV 17, 2000
		5532246	JUL 02, 2013	U-250	I-257	DEC 08, 2001
		6004968	MAR 20, 2018		PED	MAY 17, 2001
		5047407*PED	AUG 08, 2009		PED	JUN 08, 2002
		5532246*PED	JAN 02, 2014	U-250		
		6004968*PED	SEP 20, 2018			
020406 001	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
020406 002	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
>ADD> 021088 001	LEUPROLIDE ACETATE;VIADUR	6156331	JAN 30, 2017		NP	MAR 03, 2003
		5728396	JAN 30, 2017	U-316		
		5932547	JUN 13, 2017			
		5985305	JAN 30, 2017			
		6113938	JUL 24, 2018			
		6124261	JUN 13, 2017			
		6132420	JAN 30, 2017			
020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U-332		
		5547994	AUG 20, 2013	U-332		
		5760090	JAN 05, 2010	U-332		
		5844002	JAN 05, 2010	U-332		
020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U-332		
		5547994	AUG 20, 2013	U-332		
		5760090	JAN 05, 2010	U-332		
		5844002	JAN 05, 2010	U-332		
021114 001	LEVOBETAXOLOL HYDROCHLORIDE;BETAXON				NP	FEB 23, 2003
020634 001	LEVOFLOXACIN;LEVAQUIN				I-305	FEB 02, 2003
020634 002	LEVOFLOXACIN;LEVAQUIN				I-305	FEB 02, 2003
020635 001	LEVOFLOXACIN;LEVAQUIN				I-305	FEB 02, 2003
020635 002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-305	FEB 02, 2003
020635 003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-305	FEB 02, 2003
021199 001	LEVOFLOXACIN;QUIXIN	4382892	SEP 02, 2003		NDF	AUG 18, 2003
		5503407	OCT 01, 2008			
		4551456	NOV 14, 2003			
		5053407	OCT 01, 2008			
021225 001	LEVONORGESTREL;MIRENA				NP	DEC 06, 2003
019941 001	LIDOCAINE;EMLA				I-314	JAN 28, 2003
020612 001	LIDOCAINE;LIDODERM				NP	MAR 19, 2002
021130 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
021130 002	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
021131 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
021132 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
019558 001	LISINAPRIL;PRINIVIL	4374829	DEC 29, 2001			
019558 002	LISINAPRIL;PRINIVIL	4374829	DEC 29, 2001			
019558 003	LISINAPRIL;PRINIVIL	4374829	DEC 29, 2001			
019558 004	LISINAPRIL;PRINIVIL	4374829	DEC 29, 2001			

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019558 006	LISINOPRIL; PRINIVIL	4374829	DEC 29, 2001			
>ADD> 019777 001	LISINOPRIL; ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
>ADD> 019777 002	LISINOPRIL; ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
>ADD> 019777 003	LISINOPRIL; ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
>ADD> 019777 004	LISINOPRIL; ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
>ADD> 019777 005	LISINOPRIL; ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
>ADD> 019777 006	LISINOPRIL; ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
021226 001	LOPINAVIR; KALETRA	5914332	DEC 13, 2015	U-351	NC	SEP 15, 2003
		5635523	JUN 30, 2014	U-352	NCE	MAR 01, 2001
		5541206	JUL 30, 2013	U-348		
		5674882	OCT 07, 2014	U-344		
		5886036	DEC 29, 2012	U-345		
		6037157	JUN 26, 2016	U-346		
		5846987	DEC 29, 2012	U-350		
		5648497	JUL 15, 2014			
021251 001	LOPINAVIR; KALETRA	5541206	JUL 30, 2013	U-348	NC	SEP 15, 2003
		5914332	DEC 13, 2005	U-351	NCE	MAR 01, 2001
		5635523	JUN 03, 2014	U-352		
		5846987	DEC 29, 2012	U-350		
		5648497	JUL 15, 2014			
		5674882	OCT 07, 2014	U-344		
		5886036	DEC 29, 2012	U-345		
		6037157	JUN 26, 2016	U-346		
019658 001	LORATADINE; CLARITIN	4282233	JUN 19, 2002	U-77		
		4659716	APR 21, 2004	U-142		
		4863931	SEP 15, 2008			
		4282233*PED	DEC 19, 2002	U-77		
		4659716*PED	OCT 21, 2004	U-142		
		4863931*PED	MAR 15, 2009			
020641 001	LORATADINE; CLARITIN	4659716	APR 21, 2004	U-142		
		4282233	JUN 19, 2002	U-77		
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U-142		
		4863931*PED	MAR 15, 2009			
		4282233*PED	DEC 19, 2002	U-77		
		6132758	JUN 01, 2018			
020704 001	LORATADINE; CLARITIN REDITABS	4659716	APR 21, 2004	U-142		
		4282233	JUN 19, 2002	U-77		
		4371516	FEB 01, 2000			
		4863931	SEP 15, 2008			
		4659716*PED	OCT 21, 2004	U-142		
		4282233*PED	DEC 19, 2002	U-77		
		4371516*PED	AUG 01, 2000			
		4863931*PED	MAR 15, 2009			

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES	EXCLUS CODE	EXCLUS EXPIRES
019670 001	LORATADINE; CLARITIN-D	4282233	JUN 19, 2002	U-77	
		4659716	APR 21, 2004	U-142	
		4863931	SEP 15, 2008		
		4282233*PED	DEC 19, 2002	U-77	
		4659716*PED	OCT 21, 2004	U-142	
020470 001	LORATADINE; CLARITIN-D 24 HOUR	4863931*PED	MAR 15, 2009		
		4659716	APR 21, 2004	U-142	
		4282233	JUN 19, 2002	U-77	
		5314697*PED	APR 23, 2013		
		4863931	SEP 15, 2008		
		4659716*PED	OCT 21, 2004	U-142	
		4282233*PED	DEC 19, 2002	U-77	
020803 001	LOTEPREDNOL ETABONATE; ALREX	4966335	MAR 09, 2012		
		4966335	MAR 09, 2012		
020583 001	LOTEPREDNOL ETABONATE; LOTEMAX				
020938 001	MELOXICAM; MOBIC			NCE	APR 13, 2005
020049 001	MESALAMINE; PENTASA	4980173	JAN 29, 2002	U-78	
019884 001	MESNA; MESNEX	5696172	OCT 06, 2013		
020357 001	METFORMIN HYDROCHLORIDE; GLUCOPHAGE				PED SEP 03, 2000
					NCE MAR 03, 2000
					I-307 OCT 22, 2001
020357 002	METFORMIN HYDROCHLORIDE; GLUCOPHAGE				PED APR 22, 2002
					PED SEP 03, 2000
					NCE MAR 03, 2000
					I-307 OCT 22, 2001
020357 003	METFORMIN HYDROCHLORIDE; GLUCOPHAGE				PED APR 22, 2002
					NCE MAR 03, 2000
					I-307 OCT 22, 2001
					PED SEP 03, 2000
020357 004	METFORMIN HYDROCHLORIDE; GLUCOPHAGE				PED APR 22, 2002
					NCE MAR 03, 2000
					I-307 OCT 22, 2001
					PED SEP 03, 2000
020357 005	METFORMIN HYDROCHLORIDE; GLUCOPHAGE				PED APR 22, 2002
					PED SEP 03, 2000
					NCE MAR 03, 2000
					I-307 OCT 22, 2001
					PED APR 22, 2002
021202 001	METFORMIN HYDROCHLORIDE; GLUCOPHAGE XR				NDF OCT 13, 2003
021121 001	METHYLPHENIDATE HYDROCHLORIDE; CONCERTA				NP AUG 01, 2003
021121 002	METHYLPHENIDATE HYDROCHLORIDE; CONCERTA				NP AUG 01, 2003
019532 001	METOLAZONE; MYKROX	4517179	APR 29, 2003		
019815 001	MIDODRINE HYDROCHLORIDE; PROAMATINE				ODE SEP 06, 2003



PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019815 002	MIDODRINE HYDROCHLORIDE;PROAMATINE				ODE	SEP 06, 2003
020687 001	MIFEPRISTONE;MIFEPREX	4386085	JAN 08, 2002		NCE	SEP 28, 2005
		4447424	JAN 08, 2002			
		4626531	OCT 12, 2004			
021120 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE				ODE	OCT 13, 2007
020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	6127353	OCT 03, 2017			
020830 002	MONTELUKAST SODIUM;SINGULAIR	5565473	NOV 30, 2010	U-228	I-300	MAR 03, 2003
					NS	MAR 03, 2003
					NCE	FEB 20, 2003
019516 001	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
019516 002	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
019516 003	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
019516 004	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
019516 005	MORPHINE SULFATE;MS CONTIN	4366310	DEC 10, 2000			
020152 001	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
020152 002	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
020152 003	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
020152 004	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
020152 005	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
020152 006	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
020381 001	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
020381 002	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
020381 003	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
020381 004	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
		6129930	SEP 20, 2013	U-354		
020381 005	NIACIN;NIASPAN TITRATION ST	6080428	MAY 27, 2017	U-331		
020076 001	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020076 002	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020076 003	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020076 004	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020076 005	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020076 006	NICOTINE;HABITROL	5834011	MAY 01, 2007	U-355		
020536 001	NICOTINE;NICOTROL	5501236	JUN 08, 2010			
		6098632	JUN 08, 2010			
020714 001	NICOTINE;NICOTROL	6098632	JUN 08, 2010			
021134 001	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
021134 002	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
021134 003	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
019921 001	OFLOXACIN;OCUFLOX	4382892	SEP 02, 2003			
		4551456	NOV 14, 2003	U-80		
020592 001	OLANZAPINE; ZYPREXA	5817656	APR 23, 2011	U-360	I-297	MAR 17, 2003
		5817657	APR 23, 2011	U-363	I-313	NOV 09, 2003
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020592 002	OLANZAPINE; ZYPREXA	5817656	APR 23, 2011	U-360	I-297	MAR 17, 2003
		5817657	APR 23, 2011	U-363	I-313	NOV 09, 2003
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
020592 003	OLANZAPINE; ZYPREXA	5817656	APR 23, 2011	U-360	I-297	MAR 17, 2003
		5817657	APR 23, 2011	U-363	I-313	NOV 09, 2003
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
020592 004	OLANZAPINE; ZYPREXA	5817656	APR 23, 2011	U-360	I-297	MAR 17, 2003
		5817657	APR 23, 2011	U-363	I-313	NOV 09, 2003
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
020592 005	OLANZAPINE; ZYPREXA	5817656	APR 23, 2011	U-360	I-297	MAR 17, 2003
		5817657	APR 23, 2011	U-363	I-313	NOV 09, 2003
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
020592 006	OLANZAPINE; ZYPREXA	5817656	APR 23, 2011	U-360	I-297	MAR 17, 2003
		5817657	APR 23, 2011	U-363	I-313	NOV 09, 2003
		5627178	APR 23, 2011	U-364		
		5817655	APR 23, 2011	U-364		
021086 001	OLANZAPINE; ZYPREXA ZYDIS	5817655	APR 23, 2011	U-364		
		5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
021086 002	OLANZAPINE; ZYPREXA ZYDIS	5817656	APR 23, 2011	U-326		
		5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
021086 003	OLANZAPINE; ZYPREXA ZYDIS	5817656	APR 23, 2011	U-326		
		5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
021086 004	OLANZAPINE; ZYPREXA ZYDIS	5627178	APR 23, 2011	U-326		
		5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
5817656	APR 23, 2011	U-326				

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020688 001	OLOPATADINE HYDROCHLORIDE; PATANOL				I-301	MAR 20, 2003
019715 001	OLSALAZINE SODIUM; DIPENTUM	4559330	JUL 31, 2004	U-58		
020103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	5344658	SEP 06, 2011			
020103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	5344658	SEP 06, 2011			
020103 003	ONDANSETRON HYDROCHLORIDE; ZOFRAN	5344658	SEP 06, 2011		I-269	AUG 27, 2002
		5578628	JUN 24, 2006	U-44		
		4753789	JUN 24, 2006	U-44		
		4695578	JAN 25, 2005			
020605 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 25, 2005	U-183		
020781 001	ONDANSETRON; ZOFRAN ODT	5955488	NOV 14, 2015			
		6063802	NOV 14, 2015			
		5578628	JUN 24, 2006	U-330		
		4695578	JAN 25, 2005	U-330		
		4753789	JUN 24, 2006	U-329		
020781 002	ONDANSETRON; ZOFRAN ODT	5955488	NOV 14, 2015			
		6063802	NOV 14, 2015			
		5578628	JUN 24, 2006	U-330		
		4695578	JAN 25, 2005	U-330		
		4753789	JUN 24, 2006	U-330		
		6004996	JAN 06, 2018			
020766 001	ORLISTAT; XENICAL					
021014 001	OXCARBAZEPINE; TRILEPTAL				NCE	JAN 14, 2005
021014 002	OXCARBAZEPINE; TRILEPTAL				NCE	JAN 14, 2005
021014 003	OXCARBAZEPINE; TRILEPTAL				NCE	JAN 14, 2005
075184 001	PACLITAXEL; PACLITAXEL				PC	APR 21, 2001
020262 001	PACLITAXEL; TAXOL	6096331	FEB 22, 2013		D-57	JUN 20, 2003
020987 001	PANTOPRAZOLE SODIUM; PROTONIX	4758579	JUL 19, 2005		NCE	FEB 02, 2005
020819 001	PARICALCITOL; ZEMPLAR	5246925	SEP 21, 2010	U-314		
		5587497	DEC 24, 2013			
		6136799	APR 08, 2018			
020031 001	PAROXETINE HYDROCHLORIDE; PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
020031 002	PAROXETINE HYDROCHLORIDE; PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
020031 003	PAROXETINE HYDROCHLORIDE; PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6133289	MAY 15, 2015	U-358		
020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 15, 2015	U-358		
020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	6062927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-286		
020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-286		
021084 001	PERFLUOROPOLYMETHYLISOPROPYL ETHER;SKIN EXPOSURE REDUCT	5607979	MAY 30, 2015		NCE	FEB 17, 2005
020698 001	POLYETHYLENE GLYCOL 3350;MIRALAX	6048901	APR 20, 2019	U-343		
019898 002	PRAVASTATIN SODIUM;PRAVACHOL	5622985	APR 22, 2014	U-335	I-281	JUN 09, 2003
					I-304	JAN 18, 2003
					I-287	FEB 10, 2003
					I-286	JAN 18, 2003
					D-51	JAN 18, 2003

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
DOCKET NUMBER \*95S-0117  
\*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019898 003	PRAVASTATIN SODIUM;PRAVACHOL	5622985	APR 22, 2014	U-335	I-281 I-304 I-287 I-286 D-51	JUN 09, 2003 JAN 18, 2003 FEB 10, 2003 JAN 18, 2003 JAN 18, 2003
019898 004	PRAVASTATIN SODIUM;PRAVACHOL	5622985	APR 22, 2014	U-335	I-281 I-304 I-287 I-286 D-51	JUN 09, 2003 JAN 18, 2003 FEB 10, 2003 JAN 18, 2003 JAN 18, 2003
019157 001	PREDNISOLONE SODIUM PHOSPHATE;PEDIAPRED	4448774	DEC 22, 2002			
019901 001	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
019901 002	RAMIPRIL;ALTACE	5061722	OCT 19, 2008	U-3		
019901 003	RAMIPRIL;ALTACE	4587258	JAN 27, 2005		I-310	OCT 04, 2003
019901 004	RAMIPRIL;ALTACE	5061722	OCT 19, 2008	U-3		
020630 001	REMIFENTANIL HYDROCHLORIDE;ULTIVA	4587258	JAN 27, 2005		I-310	OCT 04, 2003
020630 002	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583*PED	AUG 15, 2009		NPP	OCT 15, 2002
		5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
		5019583	FEB 15, 2009		PED	JAN 12, 2002
		5466700*PED	MAR 01, 2014	U-156	NCE	JUL 12, 2001
		5019583	FEB 15, 2009		NPP	OCT 15, 2002
		5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
		5019583*PED	AUG 15, 2009		PED	JAN 12, 2002
		5466700*PED	MAR 01, 2014		NCE	JUL 12, 2001
020630 003	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583	FEB 15, 2009		NPP	OCT 15, 2002
		5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
		5019583*PED	AUG 15, 2009		PED	JAN 12, 2002
		5466700*PED	MAR 01, 2014	U-156	NCE	JUL 12, 2001
020903 001	RIBAVIRIN;REBETOL	6051252	DEC 22, 2017			
020835 001	RISEDRONATE SODIUM;ACTONEL				I-292 I-291 I-290 I-293	APR 14, 2003 APR 14, 2003 APR 14, 2003 APR 14, 2003
020835 002	RISEDRONATE SODIUM;ACTONEL	5583122	DEC 10, 2013	U-222	I-292 NCE I-291 I-293 I-290	APR 14, 2003 MAR 27, 2003 APR 14, 2003 APR 14, 2003 APR 14, 2003
020588 001	RISPERIDONE;RISPERDAL	5453425	JUL 11, 2014			
020659 001	RITONAVIR;NORVIR	5616587	JUL 11, 2014			
		6037157	JUN 26, 2016			
		5674882	OCT 07, 2014			
		5886036	DEC 29, 2012			

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020945 001	RITONAVIR;NORVIR	5648497	JUL 15, 2014		NCE	MAR 01, 2001
		5846987	DEC 29, 2012	U-347		
		5541206	JUL 30, 2013	U-348		
		5635523	JUN 03, 2014	U-347		
020823 003	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
020823 004	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
020823 005	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
020823 006	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
021025 001	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
		5602176	FEB 11, 2014	U-322		
020864 001	RIZATRIPTAN BENZOATE;MAXALT	5602162	FEB 11, 2014			
020864 002	RIZATRIPTAN BENZOATE;MAXALT	5602162	FEB 11, 2014			
021042 001	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
021042 002	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
021042 003	ROFECOXIB;VIOXX				NCE	MAY 20, 2004
021052 001	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
021052 002	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
020533 001	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN				D-64	NOV 02, 2003
020533 003	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN				D-64	NOV 02, 2003
020533 004	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN				D-64	NOV 02, 2003
020533 005	ROPIVACAINE HYDROCHLORIDE MONOHYDRATE;NAROPIN				D-64	NOV 02, 2003
021071 002	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
		5741803	APR 21, 2015	U-329		
021071 003	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
		5741803	APR 21, 2015	U-329		
021071 004	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
		5741803	APR 21, 2015	U-329		
020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-286		
		4940731	AUG 30, 2009	U-312		
021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U-246		
021179 002	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
		5667775	SEP 16, 2014	U-246		
020478 001	SEVOFLURANE;ULTANE	5990176	JAN 27, 2017		NCE	JUN 07, 2000
		6074668	JAN 09, 2018		PED	DEC 07, 2000
		5990176*PED	JUL 27, 2017			
		6074668*PED	JUL 09, 2018			
021097 001	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS;VISICOL	5616346	APR 01, 2017	U-359	NP	SEP 21, 2003
020280 006	SOMATROPIN RECOMBINANT;GENOTROPIN	4968299	JUN 28, 2008		I-302	JUN 20, 2003
					ODE	JUN 20, 2007

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES	EXCLUS CODE	EXCLUS EXPIRES
020280 007	SOMATROPIN RECOMBINANT; GENOTROPIN	4968299	JUN 28, 2008	I-302	JUN 20, 2003
020280 001	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT	5435076	APR 16, 2013	ODE	JUN 20, 2007
020280 002	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT	5716338	FEB 10, 2015	I-302	JUN 20, 2003
020280 003	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT	5435076	APR 16, 2013	ODE	JUN 20, 2007
020280 004	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT	5716338	FEB 10, 2015	I-302	JUN 20, 2003
020280 005	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT	5435076	APR 16, 2013	ODE	JUN 20, 2007
020280 008	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT	5716338	FEB 10, 2015	I-302	JUN 20, 2003
020280 009	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT	5435076	APR 16, 2013	ODE	JUN 20, 2007
020280 010	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT	5716338	FEB 10, 2015	I-302	JUN 20, 2003
020280 011	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT	5435076	APR 16, 2013	ODE	JUN 20, 2007
020280 012	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT	5716338	FEB 10, 2015	I-302	JUN 20, 2003
020280 013	SOMATROPIN RECOMBINANT; GENOTROPIN PRESERVAT	5435076	APR 16, 2013	ODE	JUN 20, 2007
019721 001	SOMATROPIN RECOMBINANT; NORDITROPIN	5633352	MAY 27, 2014	I-302	JUN 20, 2003
019721 002	SOMATROPIN RECOMBINANT; NORDITROPIN	5633352	MAY 27, 2014	ODE	JUN 20, 2007
019676 001	SOMATROPIN RECOMBINANT; NUTROPIN			D-55	APR 13, 2003
019676 002	SOMATROPIN RECOMBINANT; NUTROPIN			M-2	DEC 01, 2002
020522 001	SOMATROPIN RECOMBINANT; NUTROPIN AQ			D-55	APR 13, 2003
021075 001	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	6051259	DEC 02, 2012	M-2	DEC 01, 2002
021075 002	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	6051259	DEC 02, 2012	U-340	
021075 003	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	6051259	DEC 02, 2012	U-340	
021151 001	SOTALOL HYDROCHLORIDE; BETAPACE AF			NP	FEB 22, 2003
021151 002	SOTALOL HYDROCHLORIDE; BETAPACE AF			NP	FEB 22, 2003
021151 003	SOTALOL HYDROCHLORIDE; BETAPACE AF			NP	FEB 22, 2003
007073 002	SULFASALAZINE; AZULFIDINE EN-TABS			I-308	AUG 18, 2003
021184 001	TAZAROTENE; TAZORAC			NCE	JUN 13, 2002
021184 002	TAZAROTENE; TAZORAC			NDF	SEP 29, 2003
020256 001	TECHNETIUM TC-99M BICISATE KIT; NEUROLITE	5431900	JUL 11, 2012	NCE	JUN 13, 2002
				NDF	SEP 29, 2003
				U-336	

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019785 001	TECHNETIUM TC-99M SESTAMIBI KIT;CARDIOLITE	4894445	JAN 16, 2007	U-337		
		5324824	JAN 16, 2007			
		4885100	SEP 11, 2007			
		4988827	JAN 29, 2008			
019785 003	TECHNETIUM TC-99M SESTAMIBI KIT;MIRALUMA	4452774	SEP 09, 2004			
		4894445	JAN 16, 2007	U-337		
		5324824	JAN 16, 2007			
		4885100	SEP 11, 2007			
		4988827	JAN 29, 2008			
021124 001	TERBINAFINE HYDROCHLORIDE;LAMISIL AT	4680291	JUL 14, 2004	U-73		
		4755534	DEC 30, 2006	U-73		
		5681849	OCT 28, 2014			
021015 001	TESTOSTERONE;ANDROGEL				NDF	FEB 28, 2003
020484 001	TINZAPARIN SODIUM;INNOHEP				NCE	JUL 14, 2005
>ADD>	020912 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	6136794	JAN 29, 2019		
>ADD>	020913 001	TIROFIBAN HYDROCHLORIDE;AGGRASTAT	6136794	JAN 29, 2019		
	020771 001	TOLTERODINE TARTRATE;DETROL	5559269	MAY 05, 2015	U-318	
	020771 002	TOLTERODINE TARTRATE;DETROL	5559269	MAY 05, 2015	U-318	
	020281 001	TRAMADOL HYDROCHLORIDE;ULTRAM			PED	SEP 03, 2000
					PED	FEB 21, 2002
					NCE	MAR 03, 2000
					D-44	AUG 21, 2001
020281 002	TRAMADOL HYDROCHLORIDE;ULTRAM				PED	FEB 21, 2002
					PED	SEP 03, 2000
					NCE	MAR 03, 2000
					D-44	AUG 21, 2001
					D-63	DEC 23, 2002
>ADD>	021108 001	TRETINOIN;RENOVA			PED	JUN 23, 2003
	074973 001	TRIMETHOPRIM HYDROCHLORIDE;PRIMSOL	5763449	AUG 07, 2016	NP	AUG 31, 2003
		5962461	AUG 07, 2016			
	020326 001	TRIMETREXATE GLUCURONATE;NEUTREXIN	6017922	MAY 18, 2018		
	020326 002	TRIMETREXATE GLUCURONATE;NEUTREXIN	6017922	MAY 18, 2018		
	020715 001	TRIPTORELIN PAMOATE;TRELSTAR DEPOT	5134122	JUL 20, 2010	NCE	JUN 15, 2005
		5225205	JUL 20, 2010			
		5192741	MAR 09, 2010			
020719 001	TROGLITAZONE;PRELAY	6046202	SEP 15, 2013	U-317		
020719 002	TROGLITAZONE;PRELAY	6046202	SEP 15, 2013	U-317		
020719 003	TROGLITAZONE;PRELAY	6046202	SEP 15, 2013	U-317		
020720 001	TROGLITAZONE;REZULIN	6046202	SEP 15, 2013	U-317		
020720 002	TROGLITAZONE;REZULIN	6046202	SEP 15, 2013	U-317		
020720 003	TROGLITAZONE;REZULIN	6046202	SEP 15, 2013	U-317		
020759 001	TROVAFLOXACIN MESYLATE;TROVAN	5164402	DEC 18, 2011	U-282		
020759 002	TROVAFLOXACIN MESYLATE;TROVAN	5164402	DEC 18, 2011	U-282		



PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
 DOCKET NUMBER \*95S-0117  
 \*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021214 001	UNOPROSTONE ISOPROPYL;RESCULA	5001153	SEP 19, 2008		NCE	AUG 03, 2005
		5151444	MAR 19, 2008	U-333		
		5166178	NOV 24, 2009	U-333		
		5212200	MAY 18, 2010	U-333		
		5208256	MAY 21, 2011	U-333		
		5221763	JUN 22, 2010			
>ADD>	020487 001	4957924	JUN 23, 2009			
>ADD>		4567182	JAN 28, 2003			
>ADD>		5879706	JAN 19, 2016			
>ADD>		6107302	JAN 19, 2016			
>ADD>	020487 002	4567182	JAN 28, 2003			
>ADD>		5879706	JAN 19, 2016			
>ADD>		6107302	JAN 19, 2016			
>ADD>		4957924	JUN 23, 2009			
	020552 001	5232705	AUG 31, 2010			
		5200196	JAN 22, 2008			
		5141752	JUN 27, 2006			
		5082668	JAN 21, 2009			
		5030456	NOV 07, 2008			
		4946687	OCT 02, 2007			
		5785994	OCT 22, 2009	U-315		
		6096339	APR 04, 2017	U-365		
		6146662	NOV 14, 2017	U-366		
	020552 002	5232705	AUG 31, 2010			
		5200196	JAN 22, 2008			
		5141752	JUN 27, 2006			
		5082668	JAN 21, 2009			
		5030456	NOV 07, 2008			
		4946687	OCT 02, 2007			
		5785994	OCT 22, 2009	U-315		
		6096339	APR 04, 2017	U-365		
		6146662	NOV 14, 2017	U-366		
	021119 001	5707608	AUG 02, 2015		NCE	APR 12, 2005
		6074666	FEB 05, 2012			
		4920143	APR 24, 2007			
		5095030	APR 24, 2007			
		5214036	MAY 25, 2010			
		5770619	JAN 06, 2015	U-357		
		5798349	AUG 25, 2015	U-357		
		5756541	MAR 11, 2016	U-357		
	020547 001	5583152	SEP 26, 2010			
		6143775	DEC 11, 2011			
	020547 003	4859692	SEP 26, 2010		NCE	SEP 26, 2001
		5294636	DEC 11, 2011		I-268	SEP 17, 2002
		5319097	DEC 11, 2011		NS	SEP 17, 2002
		5482963	JAN 09, 2013			
		5583152	SEP 26, 2010			
		5612367	MAR 18, 2014	U-189		
		6143775	DEC 11, 2011			

PATENT TERM EXTENSION AND NEW PATENTS - January 19, 2001  
DOCKET NUMBER \*95S-0117  
\*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES	EXCL CODE	EXCLUS EXPIRES
021036 001	ZANAMIVIR;RELENZA			I-294	APR 26, 2003
020789 001	ZONISAMIDE;ZONEGRAN			NCE	MAR 27, 2005